title: Nanoantibodies for detection and blocking of bioactivity of human vascular endothelial growth factor A(165).
abstract: Nanoantibodies (single-domain antibodies, nanobodies) derived from noncanonical single-chain immunoglobulins provide an attractive tool for in vitro and in vivo diagnostics as well as for development of targeted drugs for clinical use. Nanoantibodies against several clinically important targets have been developed and are actively investigated. However, no development of nanoantibodies against vascular endothelial growth factor VEGF-A(165) has been reported. We describe here the generation of nanoantibodies derived from single-chain Bactrian camel immunoglobulins directed against VEGF-A(165). We demonstrate that these nanoantibodies are suitable for enzyme-linked immunoassay to quantify human VEGF-A(165) as well as for blocking its activity. Our results provide a basis for diagnostic kit development for quantification of VEGF-A(165), which emerges as a biomarker useful in various pathological conditions. In addition, the nanoantibodies might be used for development of therapeutic molecules targeting VEGF-A(165)-dependent pathological neoangiogenesis.
authors: Institute of Gene Biology, Russian Academy of Sciences, ul. Vavilova 34/5, 119334 Moscow, Russia.
authors: S V
authors: SV
authors: Tillib
authors: T I
authors: TI
authors: Ivanova
authors: E Yu
authors: EY
authors: Lyssuk
authors: S S
authors: SS
authors: Larin
authors: A V
authors: AV
authors: Kibardin
authors: E V
authors: EV
authors: Korobko
authors: P N
authors: PN
authors: Vikhreva
authors: N V
authors: NV
authors: Gnuchev
authors: G P
authors: GP
authors: Georgiev
authors: I V
authors: IV
authors: Korobko
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D019138:Antibodies, Blocking / Q000276:immunology / Q000627:therapeutic use; D016466:CHO Cells; D002162:Camelus; D061505:Cell Surface Display Techniques; D006224:Cricetinae; D004797:Enzyme-Linked Immunosorbent Assay; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects / Q000276:immunology; D006801:Humans; D049329:Nanostructures / Q000627:therapeutic use; D009389:Neovascularization, Pathologic / Q000628:therapy*; D057127:Single-Chain Antibodies / Q000235:genetics / Q000302:isolation & purification / Q000627:therapeutic use; D061905:Single-Domain Antibodies / Q000276:immunology* / Q000302:isolation & purification / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis* / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D019138:Antibodies, Blocking; D057127:Single-Chain Antibodies; D061905:Single-Domain Antibodies; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A